Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Sumitomo Chemical Company, Limited    4005   JP3401400001


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Sumitomo Chemical : Invests in a U.S. Startup Aiming to Develop Innovative Technology Utilizing Synthetic Biology

share with twitter share with LinkedIn share with facebook
share via e-mail
10/15/2019 | 09:21am EDT

Sumitomo Chemical has invested US $10 million in SweeGen Inc., a U.S. company that recently launched next-generation stevia-based sweeteners. SweeGen is a member of the U.S.-based start-ups group including Conagen, Inc. as a core company.

This investment is intended to strengthen Sumitomo Chemical's strategic collaborative relationship with SweeGen as well as with their affiliated companies, aiming to establish an array of innovative technologies by combining specialized expertise from synthetic biology and a reservoir of the Company's proprietary technologies together. The collaboration will enable Sumitomo Chemical to accelerate creating or developing the Company's next-generation businesses in its identified priority areas, such as healthcare and reducing environmental impact.

Perceiving climate change and environmental conservation as vital problems facing society and in an effort to solve the problems, Sumitomo Chemical has been focusing on effective utilization of not only chemical synthesis, but also biosynthesis, which is less dependent on fossil resources. By promoting global collaboration with a group of startups having distinctive expertise in synthetic biology, Sumitomo Chemical intends to develop cost-competitive new processes that will contribute to reducing environmental impact or make those high-performance materials that have been considered difficult to obtain via chemical synthesis. As part of these initiatives, Sumitomo Chemical began a joint research several years ago on the biosynthesis of existing chemicals with Conagen, which has an integrated technological capability from designing and culturing of microorganisms to industrialization of fermentation processes. At the same time, the two companies have been discussing joint development of new high-performance materials. Such collaboration and close dialogue have led Sumitomo Chemical to decide on making the investment announced this time.

SweeGen has recently launched next-generation stevia-based sweeteners successfully under a technology license from Conagen, aiming to create a new market for sweeteners as functional food ingredients. The launched sweeteners are drawing attention from the beverage and food industry in their unique features in that they are natural materials-derived, non-GMO, non-calorie, and also more sugar-like in taste than conventional stevia-based sweeteners. From a global perspective, there is a surging demand worldwide for greater use of low-calorie sweeteners as a sugar substitute for a number of reasons. For one thing, an increasing number of people are more conscious of their health than in the past. In addition, the World Health Organization urged all countries in 2016 to impose a tax on sugary drinks as part of measures to prevent lifestyle diseases and obesity. As a result, sugar taxes have been introduced in countries of Europe, Southeast Asia, etc. Given the circumstances, demand for next-generation sweeteners is likely to grow rapidly in the future, and SweeGen is working vigorously to build new production plant and enhance its development and sales capabilities.

SweeGen being thus about to launch the business on a full-fledged scale, Sumitomo Chemical has decided that the time is ripe for the Company to make investment in SweeGen and further deepen and broaden the collaboration with Conagen and SweeGen. Looking to the future, Sumitomo Chemical will make the best use of a SweeGen plant to develop innovative technologies associated with downstream processes (refining and waste water treatment), and will commercially adopt the technologies to produce high-performance materials at its own plants.

Under its Corporate Business Plan for FY2019 to FY2021, Sumitomo Chemical has identified accelerated development of next-generation businesses as one of its basic policies, and is currently building its own innovation ecosystem geared to create new businesses in all of its four priority areas, i.e. healthcare, reducing the impact on the environment, food, and ICT. Sumitomo Chemical will continue efforts to gain access to unique technologies of others through open innovation-oriented interactions with start-ups, academia and others, and then combine such technological expertise with its proprietary technologies to develop new technologies or create new business domains that will serve to realize a sustainable society.

About Conagen

Conagen is advancing the ways natural products are manufactured with molecule-per-molecule precision and customization. Conagen uncovers the metabolic pathways of nature, engineers unique microbes with synthetic biology, and develops high-quality products through specialized fermentation. Conagen delivers innovation to the food and beverage, flavor and fragrance, nutrition, renewable materials, and pharma markets.

About SweeGen

SweeGen, Inc. is dedicated to the development, production and distribution of non-caloric sweeteners, utilizing the technology of synthetic biology, for the food, flavor and beverage industries. SweeGen's robust product pipeline, intellectual property portfolio, and dedicated manufacturing capacity and R&D provide the foundation for innovation and delivery of high-quality sweeteners.


TEL: +81-3-5543-5102

FAX: +81-3-5543-5901

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SUMITOMO CHEMICAL COMPANY, LIMITED -3.77% 306 End-of-day quote.-3.16%
SWEEGEN, INC. 0.00% 3.55 Delayed Quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
04/06SUMITOMO DAINIPPON PHARMA : GHIT Fund Awards Grant for the Development of a New ..
04/02SUMITOMO CHEMICAL : Invests in Conagen, U.S. Bio-Venture
04/02SUMITOMO CHEMICAL : Completes Acquisition of Four South American Subsidiaries of..
04/01SUMITOMO DAINIPPON PHARMA : Donations to the Kitasato Institute's Project for CO..
03/30SUMITOMO CHEMICAL COMPANY, LIMITED : Ex-dividend day for final dividend
03/26SUMITOMO DAINIPPON PHARMA : Announces Approval of Atypical Antipsychotic Agent, ..
03/26SUMITOMO DAINIPPON PHARMA : Announces the Approval of RETHIO for an Additional I..
03/18SUMITOMO DAINIPPON PHARMA : Announces Change in Executive Officer and Other Key ..
03/16SUMITOMO CHEMICAL : Launches New Horticultural Fungicide KANAME Flowable in Japa..
03/04SUMITOMO DAINIPPON PHARMA : Discovering and designing drugs with artificial inte..
More news
Financials (JPY)
Sales 2020 2 259 B
EBIT 2020 135 B
Net income 2020 49 359 M
Debt 2020 1 124 B
Yield 2020 5,41%
P/E ratio 2020 10,3x
P/E ratio 2021 9,74x
EV / Sales2020 0,72x
EV / Sales2021 0,71x
Capitalization 510 B
Duration : Period :
Sumitomo Chemical Company, Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO CHEMICAL COMPANY,
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 445,91  JPY
Last Close Price 312,00  JPY
Spread / Highest target 89,1%
Spread / Average Target 42,9%
Spread / Lowest Target -18,3%
EPS Revisions
Keiichi Iwata President & Representative Director
Masakazu Tokura Chairman
Keigo Sasaki Head-Corporate Communication & Finance
Hiroshi Ueda Director & Vice President
Rei Nishimoto Director
Sector and Competitors
1st jan.Capitalization (M$)
BASF SE-32.20%45 609
DUPONT DE NEMOURS, INC.-39.47%28 733
ROYAL DSM-6.98%19 939